J
JUPITER NEUROSCIENCES, INC.
Period
FY 2025
Revenue
—
Net Income
$-8.64M
Total Assets
$5.56M
Equity
$-1.83M
Shares Out
36.28M
Op. Cash Flow
$-5.41M
Business
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company developing treatments for neuroinflammation and rare diseases using its proprietary JOTROL™ resveratrol platform. The company is advancing a Phase IIa trial in Parkinson's Disease and plans studies in Mild Cognitive Impairment, Alzheimer's Disease, and rare orphan conditions. In parallel, Jupiter launched Nugevia, a direct-to-consumer premium supplement line leveraging JOTROL™ technology for longevity and wellness. The company operates virtually, partnering with clinical research organizations, manufacturers, and regulatory consultants, while exploring out-licensing opportunities in Asian markets.
Summary from 10-K filed 2026-04-01
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Product Revenues, net | 21,796 | 0 | — | |
| Cost of goods sold | 4,231 | — | — | |
| Gross Profit | 17,565 | — | — | |
| Research and development | 2 | 492,660 | 954,793 | |
| General and administrative | 7 | 3 | 3 | |
| Total operating expenses | 9 | 3 | 4 | |
| Operating loss | −9 | −3 | −4 | |
| Interest income | — | 5,557 | 482 | |
| Loss on change in fair value of derivative liability | — | −53,257 | 148,751 | |
| Gain on change in fair value of convertible notes | 281,932 | — | — | |
| Interest expense | −66,020 | −248,366 | −218,705 | |
| Gain on extinguishment of debt | — | 857,723 | — | |
| Other income | 47,912 | 90,000 | 44,500 | |
| Total other expenses, net | 263,824 | 651,657 | −912,918 | |
| Net income (loss) | −9 | −2 | −5 | |
| Basic (per share) | −0.25 | −0.08 | −0.18 | |
| Diluted (per share) | −0.25 | −0.08 | −0.18 | |
| Basic (shares) | 35 | 29 | 26 | |
| Diluted (shares) | 35 | 29 | 26 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash | 4 | 4 | 28,478 | — | |
| Account receivable | 2,637 | — | — | — | |
| Prepaid contracts | 766,667 | 766,667 | — | — | |
| Inventory, net | 159,790 | — | — | — | |
| Other current assets | 106,542 | 114,086 | — | — | |
| Total current assets | 5 | 5 | 28,739 | — | |
| Operating lease right of use asset, net | 23,214 | 69,642 | 116,070 | — | |
| Prepaid contracts, noncurrent | 712,055 | 1 | — | — | |
| Other assets | 3,783 | 3,783 | 3,783 | — | |
| Total assets | 6 | 6 | 148,592 | — | |
| Accounts payable and accrued expenses | 638,646 | 396,483 | 546,014 | — | |
| Accrued compensation | 1 | 1 | 2 | — | |
| Accrued interest | 39,829 | 1,064 | 88,000 | — | |
| Deferred revenue | 735 | — | — | — | |
| Current portion of operating lease liability | 21,247 | 50,082 | 48,213 | — | |
| Convertible notes payable, fair value | 5 | — | 2 | — | |
| Other liability | — | — | — | — | |
| Total current liabilities | 7 | 2 | 6 | — | |
| Operating lease liability, net of current portion | — | 21,247 | 71,329 | — | |
| Total liabilities | 7 | 2 | 6 | — | |
| Commitments and Contingencies (Note 8) | — | — | — | — | |
| Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively | 3,444 | 3,310 | 2,652 | — | |
| Additional paid in capital | 33 | 30 | 18 | — | |
| Accumulated deficit | −35 | −26 | −24 | — | |
| Total stockholders deficit | −2 | 4 | −6 | −7 | |
| Total liabilities and stockholders deficit | 6 | 6 | 148,592 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Amortization of debt discounts | — | 43,288 | 16,712 | |
| Loss (Gain) on extinguishment of debt | — | −857,723 | — | |
| Gain on forgiveness of accrued compensation | — | −40,000 | — | |
| Amortization of prepaid contracts | 766,666 | 54,612 | — | |
| Non-cash financing cost | 200,000 | — | — | |
| Interest expense paid through sale of common stock | 22,521 | — | — | |
| Stock-based compensation | 2 | 2 | 1 | |
| Increase in accounts receivable | −2,637 | — | — | |
| Decrease (increase) in prepaid contracts | — | −2 | — | |
| Increase in prepaid and other current assets | — | −113,826 | — | |
| Increase in inventory | −159,790 | — | — | |
| Increase in other current assets | 7,544 | — | 4,971 | |
| Decrease in operating lease right of use asset | −3,654 | −1,785 | 25 | |
| Increase in deferred revenue | 735 | — | — | |
| Increase in accounts payable and accrued expenses | 242,163 | −149,530 | 164,881 | |
| Decrease in accrued compensation | −17,736 | −46,948 | 2 | |
| Increase in accrued interest | 38,765 | 46,368 | 38,270 | |
| Net cash used in operating activities | −5 | −4 | −480,953 | |
| Proceeds from note payable, related parties | — | 138,500 | 390,000 | |
| Payment on convertible note payable | — | −150,000 | — | |
| Proceeds from issuance convertible note payable, net | 6 | — | — | |
| Proceeds from offering, net of offering costs | — | 10 | — | |
| Proceeds from sale of common stock | — | 150,000 | 55,000 | |
| Net cash provided by financing activities | 5 | 8 | 445,000 | |
| Net Change in Cash | 19,832 | 4 | −35,953 | |
| Cash paid for interest | 38,426 | 147,776 | — | |
| Restricted stock issued for forgiveness of salary | — | 10,000 | 2 | |
| Stock options issued for forgiveness of salary | — | 50,000 | 3 | |
| Notes payable, related party assign to Note payable | — | 266,667 | — | |
| Stock issued in connection with convertible promissory notes | 200,000 | 636,866 | — | |
| Stock issued in connection interest payment | 22,521 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is JUPITER NEUROSCIENCES, INC.'s CIK number?
JUPITER NEUROSCIENCES, INC.'s SEC CIK number is 0001679628 (1679628). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find JUPITER NEUROSCIENCES, INC.'s SEC filings?
All of JUPITER NEUROSCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.